Reuters logo
4 years ago
AstraZeneca to buy oncology-focused Spirogen for up to $440 mln
October 15, 2013 / 6:28 AM / 4 years ago

AstraZeneca to buy oncology-focused Spirogen for up to $440 mln

LONDON, Oct 15 (Reuters) - British drugmaker AstraZeneca said on Tuesday its MedImmune unit would buy biotech company Spirogen for up to $440 million to bolster its oncology portfolio.

Privately held Spirogen focuses on antibody-drug conjugate technology, which has the potential to directly target cancer tumours while safeguarding healthy cells, AstraZeneca said.

AstraZeneca said it would pay an intial $200 million plus a further $240 million if Spirogen meets development targets. It will also pay $20 million to take an equity investment in ADC Therapeutics, which has a licensing agreement with Spirogen.

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below